DE3585696D1 - Lyophilisierte hepatitis-b-vakzine. - Google Patents

Lyophilisierte hepatitis-b-vakzine.

Info

Publication number
DE3585696D1
DE3585696D1 DE8585102824T DE3585696T DE3585696D1 DE 3585696 D1 DE3585696 D1 DE 3585696D1 DE 8585102824 T DE8585102824 T DE 8585102824T DE 3585696 T DE3585696 T DE 3585696T DE 3585696 D1 DE3585696 D1 DE 3585696D1
Authority
DE
Germany
Prior art keywords
hepatitis
vaccine
lyophilized
antigen
lyophilized preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8585102824T
Other languages
English (en)
Inventor
Nobuya Ohtomo
Kyosuke Mizuno
Fukusaburo Hamada
Hiroshi Mizokami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12809733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3585696(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Application granted granted Critical
Publication of DE3585696D1 publication Critical patent/DE3585696D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE8585102824T 1984-03-13 1985-03-12 Lyophilisierte hepatitis-b-vakzine. Expired - Fee Related DE3585696D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59048669A JPS60193925A (ja) 1984-03-13 1984-03-13 凍結乾燥製剤化ワクチン

Publications (1)

Publication Number Publication Date
DE3585696D1 true DE3585696D1 (de) 1992-04-30

Family

ID=12809733

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585102824T Expired - Fee Related DE3585696D1 (de) 1984-03-13 1985-03-12 Lyophilisierte hepatitis-b-vakzine.

Country Status (8)

Country Link
US (1) US4710378A (de)
EP (1) EP0156242B1 (de)
JP (1) JPS60193925A (de)
KR (1) KR930002263B1 (de)
AT (1) ATE74012T1 (de)
AU (1) AU576223B2 (de)
CA (1) CA1240265A (de)
DE (1) DE3585696D1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62162963A (ja) * 1986-01-10 1987-07-18 Sadao Shiosaka 金属コロイド粒子を担体とする低分子物質に対する特異抗体の作成法
IT1204400B (it) * 1986-06-20 1989-03-01 Sclavo Spa Composizioni farmaceutiche contenente una calcitonina
EP0294071A3 (de) * 1987-06-03 1990-08-01 Merck & Co. Inc. Impfstoffe gegen Hepatitis B hergestellt mit vorherhergestellten Aluminiumhydroxydengelen und Verfahren zu deren Herstellung
US4894444A (en) * 1987-07-16 1990-01-16 Merck & Co., Inc. Recovery and purification of immunogens from immunogen-alum complexes
CA1331133C (en) * 1988-03-01 1994-08-02 Michael Jon Pikal Pharmaceutical growth hormone formulations
JPH085804B2 (ja) * 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
US5032405A (en) * 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
WO1993012815A1 (en) * 1991-12-27 1993-07-08 Gensci Limited Method for obtaining recombinant surface antigen of hepatitis b, antigen and vaccine based on it
EP0835663B1 (de) * 1992-05-23 2009-09-30 GlaxoSmithKline Biologicals S.A. Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
JP3583128B2 (ja) * 1993-01-08 2004-10-27 シーエスエル、リミテッド ワクチン製剤
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6407218B1 (en) 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
US20040213798A1 (en) * 2000-06-08 2004-10-28 Powderject Vaccines, Inc. Spray-dried alum compositions
US20020120228A1 (en) * 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
GB0017999D0 (en) * 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
EP1752189A3 (de) 2001-04-20 2007-02-21 Alza Corporation Mikroprojektionsanordnung mit einem Überzug, der ein vorteilhaftes Mittel enthält
US7963935B2 (en) 2001-04-20 2011-06-21 Alza Corporation Microprojection array having a beneficial agent containing coating
US20020193729A1 (en) * 2001-04-20 2002-12-19 Cormier Michel J.N. Microprojection array immunization patch and method
AU2007203302B2 (en) * 2001-04-20 2010-07-01 Alza Corporation Microprojection array immunization patch and method
EP1399131A2 (de) * 2001-06-08 2004-03-24 Powderject Vaccines, Inc. Sprüh- gefriergetrockneten zubereitungen
AU2003225057A1 (en) * 2002-04-19 2003-11-03 The Regents Of The University Of Michigan Polymer compositions that stabilize and control the release of formaldehyde-treated vaccine antigens
CN1218750C (zh) * 2003-06-06 2005-09-14 长春生物制品研究所 皮内注射用重组乙型肝炎卡介苗联合疫苗及制备方法
US9050352B2 (en) * 2003-10-16 2015-06-09 Stephen John Ralph Immunomodulating compositions and uses therefor
AU2004311630A1 (en) * 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
CA2554755A1 (en) * 2004-01-28 2005-08-11 Cytimmune Sciences, Inc. Functionalized colloidal metal compositions and methods
TWI398272B (zh) * 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
WO2008039171A2 (en) * 2005-08-08 2008-04-03 Oregon Health & Science University Inactivating pathogens with hydrogen peroxide for vaccine production
CN101360821A (zh) * 2005-11-21 2009-02-04 圣诺菲·帕斯图尔有限公司 重组病毒的稳定制剂
DK2829282T3 (en) * 2007-03-22 2018-01-02 Univ Colorado Regents Process for preparing an immunologically active adjuvant-linked dried vaccine composition
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
CA2706700A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
TW201043267A (en) * 2009-03-19 2010-12-16 Intervet Int Bv In situ constituting a vaccine for administration to a predetermined herd of animals
EP2552478B1 (de) 2010-03-31 2016-12-21 Stabilitech Ltd. Hilfsstoffe zur stabilisierung von viralen partikeln
GB2499480A (en) 2010-03-31 2013-08-21 Stabilitech Ltd Method for preserving alum adjuvants and alum-adjuvanted vaccines
JP5960120B2 (ja) 2010-03-31 2016-08-02 スタビリテック リミテッド ウイルス粒子の安定化
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
US10357559B2 (en) * 2013-12-27 2019-07-23 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
US11273127B2 (en) 2014-05-06 2022-03-15 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for thermally stable multi-targeted antigens
BR112016025977A2 (pt) * 2014-05-06 2017-10-31 Univ Colorado Regents composições, métodos e utilizações para formulações de papilomavirus humano estábulo estável
TWI745278B (zh) * 2014-10-10 2021-11-11 以色列商艾畢克生物實驗有限公司 發泡性降低之疫苗組合物
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
CN112675134A (zh) * 2020-12-29 2021-04-20 深圳康泰生物制品股份有限公司 重组乙型肝炎抗原冻干保护剂、重组乙型肝炎抗原冻干疫苗及其制备方法
CN112717902B (zh) * 2020-12-31 2022-05-17 武汉瑞法医疗器械有限公司 一种乙型肝炎病毒吸附剂及其制备方法与应用
WO2022168889A1 (ja) * 2021-02-03 2022-08-11 応用酵素医学研究所株式会社 微粒子粉末剤型粘膜ワクチン

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617457A1 (de) * 1966-12-16 1972-04-20 Erba Carlo Spa Verfahren zur Stabilisierung von Zubereitungen interferierender Virusprodukte
US3636191A (en) * 1969-10-08 1972-01-18 Cancer Res Inst Vaccine against viral hepatitis and process
US4164565A (en) * 1975-03-14 1979-08-14 New York Blood Center, Inc. Vaccine for active immunization containing hepatitis B surface antigen and associated antigen
JPS5936698A (ja) * 1982-08-20 1984-02-28 Science & Tech Agency Ｂ型肝炎ウイルス遺伝子を組込んだ組換えｄｎａおよび形質転換動物細胞
JPS59101426A (ja) * 1982-11-29 1984-06-12 Green Cross Corp:The Ｂ型肝炎感染予防用ワクチンの製造方法
JPS6013718A (ja) * 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン

Also Published As

Publication number Publication date
CA1240265A (en) 1988-08-09
AU576223B2 (en) 1988-08-18
KR930002263B1 (ko) 1993-03-27
US4710378A (en) 1987-12-01
KR850006450A (ko) 1985-10-05
AU3982285A (en) 1985-09-19
ATE74012T1 (de) 1992-04-15
EP0156242A3 (en) 1988-07-20
EP0156242B1 (de) 1992-03-25
JPS60193925A (ja) 1985-10-02
EP0156242A2 (de) 1985-10-02
JPH0439445B2 (de) 1992-06-29

Similar Documents

Publication Publication Date Title
DE3585696D1 (de) Lyophilisierte hepatitis-b-vakzine.
AU572162B2 (en) Hepatitis b vaccine
ES2059612T3 (es) Vacuna con coadyuvante, combinada para la hepatitis a, b.
ES2002490A6 (es) Un metodo de preparar un virus recombinante
DK0608261T3 (da) Sammensætninger med immunreaktivt hepatitis C virus polypeptid
FI935808A (fi) Hepatit-C-virus (HCV) polypeptider
KR950701822A (ko) 간염B 표면 항원 및 다른 항원으로 구성된 조합 백신(Combined vaccines comprising hepatitis B surface antigen and other antines)
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
MX26715A (es) Procedimiento para la preparacion de particulas antigenicas del virus de la hepatitis b en levaduras metilotroficas.
PT586076E (pt) Vacinas de adenovirus recombinantes
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
FI113621B (fi) Menetelmä rekombinanttiadenovirusrokotteiden valmistamiseksi
Hanson et al. Demonstration of antibodies of different immunoglobulin types to the O-antigen of the infecting E. coli strain in infants and children with pyelonephritis
DK0563254T3 (da) Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
TH2141EX (th) วัคซีนสำหรับตับอักเสบชนิด b
TH3859EX (th) เฮพาไททีส บี วัคซีนแห้งโดยการแช่แข็งภายใต้การลด ความดัน (กรรมวิธี)
DE2962921D1 (en) Feline infectious peritonitis vaccine and process for its preparation
ES515472A0 (es) Procedimiento para proteger anfitriones susceptibles de infeccion de hepatitis.
DE69322960T2 (de) Empfängnisverhütender impfstoff
EP0293201A3 (de) Methode zur Impfung gegen Hepatitis-B-Virus
ES2155436T3 (es) Proteinas recombinantes con la reactividad inmunologica del antigeno e del virus de la hepatitis b (hbeag), procedimiento para su preparacion y su utilizacion en analisis inmunologicos y en vacunas.
NO931821L (no) Hepatitt b vaksinepreparat som omfatter et gallesyresalt
DK541286D0 (da) Fermentationsmetoder for hepatitis-vaccinefremstilling

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee